Visceral adiposity is a strong determinant of GH secretion and states of GH deficiency are associated with increased visceral adiposity, and decreased lean body mass. The purpose of our study was to determine the sensitivity and specificity of different methods of assessing body composition (anthropometry, DXA, and CT) to predict GH deficiency in premenopausal women and threshold values for each technique to predict GH deficiency, using ROC curve analysis. We studied a group of 45 healthy lean, overweight, and obese premenopausal women who underwent anthropometric measurements (BMI, waist and hip circumferences, skin fold thickness), DXA, CT and a GHRH-arginine stimulation test. ROC curve analysis was used to determine cut-off values for each method to identify GH deficiency. Visceral adiposity measured by CT showed the highest sensitivity and specificity for identifying subjects with GH deficiency with a cut-off of >9962 mm 2 (AUC: 0.95, sensitivity:100%, specificity:77.8%, p=0.0001). Largest waist circumference showed high sensitivity and specificity with a cut-off of >101.7 cm (AUC: 0.89, sensitivity:88.9%, specificity:75%, p=0.0001). When comparing the ROC curves of visceral fat measured by CT and largest waist circumference, the difference between the two methods was not statistically significant (p=0.36). Our study showed that the largest waist circumference predicts the presence of GH deficiency in healthy premenopausal women with high sensitivity and specificity and nearly as well as CT measurement of visceral adiposity. It can be used to identify women in whom GH deficiency is likely and therefore in whom formal GH stimulation testing might be indicated.
Introduction
Obesity is highly prevalent in the western world, and visceral adiposity is an independent predictor of metabolic complications such as dyslipidemia, type 2 diabetes and cardiovascular disease (25, 35) . Prior studies have established that visceral adiposity is a strong determinant of growth hormone (GH) secretion (11, 31, 32) , and that GH plays a role in modulating body composition. States of GH deficiency are associated with increased body fat, including visceral adiposity, and decreased lean body mass (10, 14) ; whereas states of GH excess are associated with decreased body fat and increased lean body mass (4).
The GHRH-arginine stimulation test is a sensitive and specific test for diagnosing GH deficiency, and a cut-off limit of 5 ng/ml has been used to diagnose GH deficiency in adults (6) . However, this test is invasive, time-consuming, and expensive. Should GH deficiency be determined to be a treatable condition in young women with visceral adiposity, it would be useful to be able to perform a simple body composition measurement to identify subjects who may be at risk for GH deficiency and for whom formal GH simulation testing may be more likely to yield a positive result. Computed tomography (CT) can quantify visceral and subcutaneous fat depots (7) and is the gold standard for measuring visceral fat. However, it is expensive and involves radiation exposure. Several clinical methods, including anthropometry, and dual energy X-ray absorptiometry (DXA), have been used as surrogates for estimating body fat (8, 15, 19, 4 20, 27, 28, 34) , but these measurements do not allow for the evaluation of visceral fat content. The purpose of our study was to compare sensitivity and specificity of simple less invasive measures of body composition, such as anthropometry to CT and DXA to predict GH deficiency in a group of lean, overweight, and obese premenopausal women.
In addition, we wanted to determine threshold values for each technique to predict GH deficiency, using receiver operator characteristic (ROC) curve analysis. 
Materials and Methods
The study was approved by the institutional review board of Partners Healthcare Inc. and was Health Insurance Portability and Accountability Act compliant. Written informed consent was obtained from all subjects prior to the study.
Subjects
The study group comprised 45 healthy premenopausal women who were recruited from the community through advertisements. Exclusion criteria included hypothalamic or pituitary disorders, diabetes mellitus or other chronic illnesses, estrogen or glucocorticoid use and weight greater than 280 pounds (due to the limitations of the DXA and CT scanners). Participants were admitted to the General Clinical Research Center at the Massachusetts General Hospital, where testing was performed. Each participant underwent anthropometric measurements, DXA, and CT, as detailed below, and a GHRH-arginine stimulation test. For the GHRH-arginine stimulation test, GHRH 1 mcg/kg plus arginine 0.5 g/kg (maximum 30 gm) IV were administered and GH levels drawn at baseline and every 30 minutes for two hours (6) . GH deficiency was based on standard criteria used to diagnose adults with hypopituitarism (peak GH after stimulation with GHRH and arginine <5ng/ml) (6). Clinical characteristics, peak GH after GHRHarginine stimulation, and fat mass, measured by DXA, have been previously published Serum samples were collected and stored at -80˚ C. Serum GH was measured using an immunoradiometric assay (IRMA) kit, with a minimum detection limit of 0.01 ng/ml, an intra-assay coefficient of variation (cv) of 3.1-5.4% and an inter-assay cv of 5.9-11.5%.
Anthropometry
Body weight was measured at a standard balance beam scale to the nearest 0.1 kg in triplicate and averaged. Height was measured barefoot to the nearest 0.1cm in triplicate and averaged. Body mass index (BMI) was calculated as weight divided by height squared (kg/m 2 ).
Skin fold thickness of the triceps, biceps, subscapular and suprailiac areas was measured using metal calipers in triplicate and averaged. Skin fold measurements were used to estimate % body fat.
Body circumferences were measured at the waist at the smallest circumference between the lowest rib and iliac crest, at the level of the umbilicus, the midpoint between the lowest rib and iliac crest, the iliac crest, and at the hip using a metal tape to the nearest 0.1 cm in triplicate and averaged. The largest circumference represents the largest value obtained from the above measures. Iliac waist-to-hip and largest hip-to-waist ratios were determined from the circumferential measurements of the waist at the level of the umbilicus and the hips at the level of the iliac crest taken with the patient in a standing position. Since this was an exploratory study we did not perform a validation study. However, we performed a cross validated error estimate to determine the error estimate for each measure.
Power calculation: The t-test power was used to approximate the power of the ROC curve test. With a proposed sample size of 9 for the GH deficient and 36 for the GH sufficient group, the study will have a power of 82.3% to yield a statistically significant result, that the area under the ROC curve is greater than 0.5. This computation assumes that the mean difference is 1.1 (corresponding to means of 1.1 versus 0.0) and the common within-group standard deviation is 1.0. 
Results

Clinical Characteristics of Study Subjects
Subject characteristics are shown in Table 1 Table 2 .
Body composition determinants of GH deficiency
Results of ROC curve analyses are summarized in Table 3 . On the basis of ROC curves, visceral adiposity measured by CT showed the highest sensitivity and specificity for identifying subjects with GH deficiency. The area under the curve (AUC) was 0.95 and with a cut-off value of >9962 mm 2 , sensitivity was 100% and specificity was 77.8% (p=0.0001). Sensitivity and specificity of the cross validated error estimate were 89% and 75%, respectively. The largest waist circumference was the umbilical waist circumference in 75% of patients. Largest waist circumference showed high sensitivity and specificity when a cut-off value of >101.7 cm was used (AUC: 0.89, sensitivity 88.9%, specificity 75%, p=0.0001). Sensitivity and specificity of the cross validated error estimate were 67% and 72%, respectively. Using a cut-off value of >80cm for largest waist circumference as used to diagnose metabolic syndrome by the International Diabetes Federation (3), sensitivity was 100% but specificity was only 9%. Using a cutoff value of >88cm for the largest waist circumference as proposed by Lean at al (18) to determine visceral adiposity, sensitivity was 100% but specificity dropped to 25%. When comparing the ROC curves of visceral fat measured by CT and largest waist circumference (cut-off value of >101.7cm), the difference between the two methods was not statistically significant (p=0.36) (Figure 1 ).
Determination of total and trunk fat content as measured by DXA showed an AUC of 0.87 and 0.88 with sensitivity of 100% and specificity of 69.4% and 66.7% , respectively, when using a cut-off value of >16246g and >31677g, respectively (p=0.0001). Sensitivity and specificity of the cross validated error estimate were 67% and 64%, respectively for total fat and 67% and 67%, respectively, for trunk fat. Comparing ROC curves of visceral fat measured by CT and trunk fat (g) measured by DXA, the difference between the two methods was not statistically significant (p=0.36). The largest waist-to-hip ratio demonstrated an AUC of 0.85 and sensitivity was 100% and specificity was 66.6% when a cut-off value of >0.85 was used (p= 0.0001). Sensitivity and specificity of the cross validated error estimate were 67% and 57%, respectively. Comparing the ROC curves of visceral fat as measured by CT and largest hip to waist ratio, the difference between the two methods was not statistically significant (p=0.3). 
Discussion
Our study showed that the largest waist circumference can predict GH deficiency in premenopausal women and that this measurement is almost as sensitive and specific for predicting GH deficiency as visceral fat measured by abdominal CT. These data may be of importance if further research confirms the association of GH deficiency with increased cardiovascular risk.
An increased prevalence of visceral adiposity and cardiovascular events has been established in women with GH deficiency due to hypopituitarism. Studies have shown that decreased GH secretion is an independent risk factor for visceral obesity and cardiovascular disease in this patient population. Higher cardiovascular mortality in female GH deficient patients than in males has been found (9, 24) . This may reflect a relatively more severe state of GH deficiency in women compared with men, as GH secretion is nearly twice as high in young, healthy women as in men (11) . Therefore, we focused our study on healthy overweight and obese women and the relationship between visceral adiposity and GH deficiency in this patient population.
Multiple studies have demonstrated decreases in visceral adiposity, without a change in overall weight or BMI in GH deficient patients during physiologic GH administration (5, 15) . Although not FDA approved for clinical use, GH replacement has been studied in subjects with visceral adiposity without pituitary or hypothalamic disease, and may improve insulin sensitivity over time, potentially due to adipose reduction. In a study by Johannsson et al. (17) , administration of low-dose GH to obese men resulted in decreased visceral fat mass, suggesting a possible therapeutic role for GH in patients with visceral obesity. In a study evaluating GH administration in obese postmenopausal women (12), 12 months of GH administration reduced the amount of visceral fat and increased thigh muscle mass, whereas no change in subcutaneous adipose tissue was observed.
Therefore, if further research confirms these effects, it might be useful to develop diagnostic tools in order to identify subjects with visceral adiposity who might be at risk for being GH deficient and in whom formal GH stimulation testing should be performed.
Sophisticated imaging modalities such as CT or MRI are able to distinguish visceral from subcutaneous fat with a high level of precision, but these methods are expensive, time consuming, and CT involves radiation exposure (2, 26) . Simple anthropometric variables such as waist circumference and waist-to-hip ratio have been used to estimate visceral adipose tissue. Several studies have indicated that the waist circumference is strongly related to health risks associated with obesity and that it correlates with visceral fat measured by CT (13, 16) . Our study showed that the largest waist circumference is an easy and reliable method that can predict GH deficiency in premenopausal women. Waist circumferences can be measured at several locations. In our study, the waist circumference measured at the umbilicus corresponded in 75% of study participants to the largest waist circumference. Visceral adiposity measured with CT showed a higher sensitivity and specificity in detecting GH deficiency than largest waist circumference.
However, the difference between the two methods was not statistically significant. On the basis of ROC curves, the most sensitive and specific cut-off was >102 cm in women for largest waist circumference. Current guidelines suggest a cut-off of >88 cm in women on the basis of detecting many metabolic risk factors (16). In our study, the specificity of detecting GH deficiency dropped from 75% to 25% when using 88cm as a cut-off. The
International Diabetes Federation suggests a cut-off value for largest waist circumference of >80 cm to diagnose metabolic syndrome. Using this cut-off value, the specificity in our study dropped to 9%. In a study by Wahrenberg et al (33) a cut-off of >100 cm was sensitive and specific for predicting insulin resistance in men and women. Based on our data, a waist circumference of >102 cm in premenopausal women provides a useful reference value to identify obese women who may be at risk for GH deficiency and who should undergo formal GH stimulation testing.
In our study, BMI and iliac waist-to-hip ratio measurements showed low sensitivity and specificity in predicting GH deficiency. Trunk and total fat as determined by DXA showed high sensitivity and specificity in detecting GH deficiency. However, sensitivity and specificity were higher for the largest waist circumference. In addition, DXA requires radiation exposure. As expected, skin fold measurements did not predict GH deficiency in our population. We performed skin fold thickness measurements of the triceps, bceps, subscapular, and suprailiac areas to present the complete spectrum of anthropometric measurements.
Our study had several limitations. First is the relatively small number of subjects who were GH deficient (n=9) compared to the GH sufficient subjects (n=36). Second, we only studied premenopausal women. There are sex-and age-related differences in the relation of waist measurement to accumulation of visceral adipose tissue (22, 23 In conclusion, the largest waist circumference predicts the presence of GH deficiency in premenopausal women without hypothalamic or pituitary disease with high sensitivity and specificity and nearly as well as CT measurement of visceral adiposity. This provides further evidence of the importance of visceral fat mass as a predictor and possible mechanism for GH deficiency in young healthy women. GH replacement has not been established to be a safe and effective treatment for young overweight or obese women and is not FDA approved. However, should GH deficiency be established to have important cardiovascular risk or metabolic consequences in the future, we raise the possibility that a simple test that can be performed in any office with a tape measure might be able to identify women in whom GH deficiency is likely and therefore in whom formal GH stimulation testing might be indicated. Table 2 Clinical characteristics of GH deficient and GH sufficient subjects. 
